The KBTBD8 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited human polyclonal knockout cell population in which the KBTBD8 gene has been disrupted in the A-549 lung adenocarcinoma cell line. This pooled format provides a heterogeneous population of cells with diverse KBTBD8 loss-of-function mutations, enabling robust evaluation of gene function while minimizing clonal artifacts. As a substrate adaptor for the Cullin-3 (CUL3)-RBX1 E3 ubiquitin ligase, KBTBD8 directs the ubiquitination and proteasomal degradation of specific target proteins, with DEPTOR serving as a critical substrate. The polyclonal nature of this model supports population-level studies of mTORC1 signaling and protein homeostasis, offering a versatile tool for dissecting ubiquitin-dependent regulatory mechanisms in cancer biology.
The A-549 host cell line, derived from a 58-year-old male with lung adenocarcinoma, exhibits adherent epithelial morphology and retains key signaling networks characteristic of non-small cell lung cancer. Widely utilized in oncology research, A-549 cells express functional mTORC1 pathway components, including mTOR, Raptor, and DEPTOR, as well as downstream effectors such as S6K1 and 4E-BP1. Their well-characterized genetic and phenotypic stability makes them an ideal chassis for studying the molecular basis of lung tumorigenesis, drug responses, and resistance mechanisms. The integration of KBTBD8 knockout into this model thus permits direct interrogation of ubiquitin-proteasome system (UPS)-mediated regulation within a clinically relevant lung cancer context.
KBTBD8 functions as the substrate recognition module within the CUL3-RBX1 E3 ligase complex, selectively recruiting DEPTOR for K48-linked polyubiquitination and subsequent 26S proteasomal degradation. This event relieves DEPTOR-mediated inhibition of mTORC1, thereby promoting kinase activity toward substrates like S6K1 and 4E-BP1, which drive protein synthesis and cell growth. Upstream, KBTBD8 expression is regulated by the NRF2 transcription factor in response to cellular stress, linking redox homeostasis to mTORC1 output. The CUL3-KBTBD8 complex interfaces with the broader mTOR signaling network, which includes the TSC complex, Rag GTPases, and GATOR1, to fine-tune growth signals. Additionally, KBTBD8 may influence cullin neddylation dynamics and interact with E2 ubiquitin-conjugating enzymes to modulate ligase activity.
In A-549 cells, disruption of KBTBD8 leads to the stabilization and accumulation of DEPTOR, which in turn suppresses mTORC1 signaling by binding to the mTOR-Raptor complex and preventing its activation. This molecular blockade reduces phosphorylation of S6K1 and 4E-BP1, ultimately impairing cap-dependent translation and cell proliferation. The resultant attenuation of anabolic metabolism and growth renders this model particularly significant for exploring mTORC1-driven oncogenic processes in lung adenocarcinoma. Furthermore, the knockout system enables assessment of how UPS dysfunction contributes to cancer cell adaptation, providing a platform for investigating the interplay between protein degradation pathways and malignant phenotypes.
This polyclonal knockout product is designed for a broad array of research applications, including mechanistic studies of mTORC1 signaling, ubiquitin-proteasome system biology, and lung cancer pathobiology. Researchers can employ Western blotting to monitor DEPTOR levels and phospho-S6K as readouts of pathway activity, while ubiquitination assays and co-immunoprecipitation of CUL3-KBTBD8 complexes provide direct insight into ligase function. RT-qPCR for mTOR-responsive genes, cell viability and colony formation assays, and apoptosis detection further characterize the functional consequences of KBTBD8 loss. Immunofluorescence staining for mTORC1 activation markers enables spatial analysis of signaling within the population. These methodologies support investigations into drug resistance mechanisms and the development of targeted therapies. For further details or to discuss customized experimental strategies, please contact Ascent Research.
